Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells

Prototypic CYP3A4 inducers were tested in a pregnane X receptor (PXR) reporter gene assay, Fa2N-4 cells, HepaRG cells, and primary human hepatocytes, along with negative controls, using CYP3A4 mRNA and activity endpoints, where appropriate. Over half of the compounds tested (14 of 24) were identified as time-dependent inhibitors of CYP3A4 and high mRNA/activity ratios (>10) were consistent with CYP3A4 time-dependent inhibition for compounds such as troleandomycin, ritonavir, and verapamil. Induction response was compared between two human donors; there was an excellent correlation in the EC50 estimates (r2 = 0.89, p < 0.001), and a weak but statistically significant correlation was noted for maximum observed induction at an optimum concentration (Emax) (r2 = 0.38, p = 0.001). Emax and EC50 estimates determined from the PXR reporter gene assay and Fa2N-4 and HepaRG cells were compared with those from hepatocytes. Overall, EC50 values generated using hepatocytes agreed with those generated in the PXR reporter gene assay (r2 = 0.85, p < 0.001) and Fa2N-4 (r2 = 0.65, p < 0.001) and HepaRG (r2 = 0.99, p < 0.001) cells. However, Emax values generated in hepatocytes were only significantly correlated to those determined in Fa2N-4 (r2 = 0.33, p = 0.005) and HepaRG cells (r2 = 0.79, p < 0.001). “Gold standard” cytochrome P450 induction data can be generated using primary human hepatocytes, but a restricted, erratic supply and interdonor variability somewhat restrict routine application within a drug discovery setting. HepaRG cells are a valuable recent addition to the armory of in vitro tools for assessing CYP3A4 induction and seem to be an excellent surrogate of primary cells.

[1]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[2]  Tommy B. Andersson,et al.  HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans , 2008, Drug Metabolism And Disposition.

[3]  Y. Berger,et al.  Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  Kathy Carroll,et al.  Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.

[5]  J. Sahi,et al.  Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line , 2004, Journal of Pharmacology and Experimental Therapeutics.

[6]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[7]  R. Riley,et al.  EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES , 2006, Drug Metabolism and Disposition.

[8]  N. Hewitt,et al.  Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro–in vivo correlations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  Willem Meuldermans,et al.  Cell-based models to study hepatic drug metabolism and enzyme induction in humans , 2005, Expert opinion on drug metabolism & toxicology.

[11]  J. Sahi,et al.  Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical , 2008, The AAPS Journal.

[12]  T. Maurer,et al.  Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction , 2006, Drug Metabolism and Disposition.

[13]  C. Masimirembwa,et al.  Evaluation of Human Liver Slices and Reporter Gene Assays as Systems for Predicting the Cytochrome P450 Induction Potential of Drugs in Vivo in Humans , 2006, Pharmaceutical Research.

[14]  X. Chu,et al.  Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction , 2008, Drug Metabolism and Disposition.

[15]  A. D. Rodrigues,et al.  Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. , 2006, Current drug metabolism.

[16]  Valérie Fessard,et al.  Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies , 2008, Drug Metabolism and Disposition.

[17]  S. Strom,et al.  Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Geraldine A Hamilton,et al.  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[19]  B. Kennedy,et al.  Refinement of an in vitro cell model for cytochrome P450 induction. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[20]  J. Castell,et al.  Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies , 2006, Expert opinion on drug metabolism & toxicology.

[21]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[22]  M. Dickins.  Induction of cytochromes P450. , 2004, Current topics in medicinal chemistry.

[23]  K. Shakesheff,et al.  Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  Sean Kim,et al.  CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[25]  C. Smith,et al.  Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  Hongbing Wang,et al.  Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes , 2003, Clinical pharmacokinetics.

[27]  Hayley S. Brown,et al.  Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.

[28]  L. Lesko,et al.  Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  J. Kenny,et al.  AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS , 2005, Drug Metabolism and Disposition.

[30]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[31]  K. Youdim,et al.  Induction of Cytochrome P450: Assessment in an Immortalized Human Hepatocyte Cell Line (Fa2N4) Using a Novel Higher Throughput Cocktail Assay , 2007, Drug Metabolism and Disposition.

[32]  S. Dehal,et al.  HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 , 2006, Drug Metabolism and Disposition.

[33]  Kristin E. D. Coan,et al.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.